The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 22 of the 31 sources its claims cite were checked for support.
Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials
Open accessAbstract
This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) when compared to metformin and placebo in the management of body weight, glucose homeostasis and hormone levels in women polycystic ovary syndrome (PCOS). A systematic search of "PubMed", "EMBASE", "Cochrane Library", "Web of Science" and "Google Scholar" was conducted up to October 2024 for randomized controlled trials involving adult women with PCOS treated with GLP-1RAs compared to metformin or placebo. The primary outcomes were changes in body mass index (BMI), body weight, waist circumference (WC), waist-to-hip ratio (WHR) and abdominal girth (AG). Secondary outcomes included glucose homeostasis (fasting glucose, fasting insulin, OGTT results and HOMA-IR), hormone levels (DHEAS, SHBG, total and free testosterone and FAI), lipid profiles (total cholesterol, HDL, LDL and triglycerides) and safety. GLP-1RAs significantly reduced BMI, body weight, WC, WHR and AG (P < 0.0001 in all cases). For glucose homeostasis, GLP-1RAs significantly reduced fasting insulin, glucose level at 2 h after OGTT, and HOMA-IR. There was also a reduction in HDL. All the other parameters measured were unchanged. In addition, GLP-1RAs increased nausea (P = 0.02), vomiting (0.04) and dizziness (0.03). GLP-1RAs effectively reduced body weight, BMI and insulin resistance in patients with PCOS, although they were accompanied by nausea, vomiting and dizziness. Further studies are needed to explore their long-term effects on glucose homeostasis and lipid profiles.
Overview
CoChat Summary
TL;DR
In this meta-analysis of 13 RCTs in adult women with PCOS, GLP-1 receptor agonists significantly reduced BMI, body weight, waist circumference, waist-to-hip ratio, abdominal girth, fasting insulin, 2-h post-OGTT glucose/insulin, and HOMA-IR compared with metformin or placebo. Benefits were accompanied by increased nausea, vomiting, and dizziness, while overall hormone and most lipid outcomes were largely unchanged.
Key findings
- Anthropometric outcomes improved significantly: BMI MD −1.59 (95% CI −2.07 to −1.10; P < 0.0001; 11 studies, 349 vs 310 subjects), body weight MD −3.57 (95% CI −5.15 to −1.99; P < 0.0001; 10 studies), WC MD −4.97 (95% CI −5.56 to −4.37; P < 0.0001), WHR MD −0.03 (95% CI −0.03 to −0.03; P < 0.0001), and AG MD −2.05 (95% CI −2.93 to −1.16; P < 0.0001).
- Glucose homeostasis was mixed: fasting glucose was not significantly reduced overall (MD −0.12; 95% CI −0.28 to 0.04; P = 0.14), but 2-h post-OGTT glucose (MD −0.54; 95% CI −1.01 to 0.07; P = 0.02), fasting insulin (MD −1.40; 95% CI −2.65 to −0.15; P = 0.03), 2-h post-OGTT insulin (MD −27.88; 95% CI −38.58 to −17.17; P < 0.0001), and HOMA-IR (MD −0.58; 95% CI −0.98 to −0.19; P = 0.004) were reduced.
- Overall hormone levels showed no significant changes for DHEAS, SHBG, total testosterone, free testosterone, or FAI; HDL was reduced (MD −0.02; 95% CI −0.04 to −0.01; P = 0.0001), while total cholesterol, LDL, and triglycerides were not significantly changed overall.
- Safety: GLP-1RAs increased nausea (OR 3.07; 95% CI 1.56–6.03; P = 0.02), vomiting (OR 2.05; 95% CI 1.04–4.06; P = 0.04), and dizziness (OR 5.58; 95% CI 1.23–25.22; P = 0.03); stomachache was lower (OR 0.15; 95% CI 0.03–0.66; P = 0.01), and diarrhea, constipation, bloating, fatigue, headache, and insomnia were not significantly increased.
Methods
- Systematic review and meta-analysis of RCTs identified from PubMed, EMBASE, Cochrane Library, Web of Science, and Google Scholar up to October 2024; 13 RCTs met inclusion criteria, including 397 participants receiving GLP-1RAs, 330 receiving metformin, and 68 receiving placebo.
- Eligible participants were adult women aged 18–45 years with PCOS; interventions were GLP-1RAs (semaglutide, liraglutide, exenatide) versus metformin or placebo, with follow-up of at least 12 weeks.
- Mean differences or odds ratios with 95% CIs were calculated using RevMan 5.0; random-effects models were used when I² > 50%, fixed-effects models when I² < 50%; subgroup analyses compared metformin versus placebo controls, and funnel plots assessed publication bias.
Limitations
- The authors state high heterogeneity across studies, variability in populations, interventions, and methodologies, and insufficient detail on concurrent background interventions, limiting stratified or sensitivity analyses.
- The authors note inconsistent effects across outcomes, especially fasting glucose and hormone levels, and caution in interpreting overall effectiveness despite funnel plots showing no publication bias.
- Evident from the text: several analyses were small or based on single studies, some subgroup confidence intervals were very wide, and some reported P values/confidence intervals appear inconsistent (e.g., 2-h post-OGTT glucose CI crossing zero with P = 0.02; FAI CI and P value mismatch), while six studies had high risk of performance bias.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
13 Valid · 2 Not valid · 4 Not checked · 141 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Since the long-term use of estrogen-progestin-based ovulation-inducing drugs and androgen-lowering treatments carry a risk of endometrial cancer, and since weight loss and the effects on IR are often minimal, clinical approaches are now seeking therapies that can simultaneously address both reproductive hormone imbalances and disturbances in glucose metabolism17.”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Introduction
What the sources say
- Disputedcites [17] Singh, S. et al. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. J. Clin. Med. 12(4), 1454 (2023). sourceExperimental — accuracy not yet measured
The Introduction attributes increased endometrial-cancer risk to PCOS pathophysiology, not to long-term medication use. Sections 5.1 (Oral Contraceptives and Anti-Androgens) and 5.3 (Ovulation Inducers) describe these treatments but do not identify endometrial cancer as a treatment risk. The claim assigns the risk to the drugs instead of the condition. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For PCOS patients with obesity and infertility, a combined treatment with metformin and liraglutide has been shown to effectively reduce body weight, improved glucose metabolism and relieved IR18.”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Introduction
What the sources say
- Partly supportedcites [18] Xing, C., Zhao, H., Zhang, J. & He, B. Effect of Metformin versus Metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 13, 945609 (2022). sourceExperimental — accuracy not yet measured
The Results (Metabolic parameters after treatment; page unavailable) report that fasting glucose, fasting insulin, and HOMA-IR decreased after 12 weeks of metformin plus liraglutide. However, the Methods (Patients; page unavailable) enrolled patients with BMI ≥24 kg/m² and did not require obesity or infertility, so the claim's specified population is not established by this study. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For PCOS patients with obesity and infertility, a combined treatment with metformin and liraglutide has been shown to effectively reduce body weight, improved glucose metabolism and relieved IR18.”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Introduction
What the sources say
- Partly supportedcites [18] Xing, C., Zhao, H., Zhang, J. & He, B. Effect of Metformin versus Metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 13, 945609 (2022). sourceExperimental — accuracy not yet measured
The Results (Menstruation and anthropometric measurements after treatment; page unavailable) report significantly reduced body weight after metformin plus liraglutide treatment. However, the Methods (Patients; page unavailable) enrolled patients with PCOS and BMI ≥24 kg/m², not specifically patients with obesity and infertility, so the claimed population is not established by this study. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For PCOS patients with obesity and infertility, a combined treatment with metformin and liraglutide has been shown to effectively reduce body weight, improved glucose metabolism and relieved IR18.”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Introduction
What the sources say
- Partly supportedcites [18] Xing, C., Zhao, H., Zhang, J. & He, B. Effect of Metformin versus Metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 13, 945609 (2022). sourceExperimental — accuracy not yet measured
The Results (Metabolic parameters after treatment; page not specified) report significantly lower HOMA-IR after 12 weeks of metformin plus liraglutide, supporting the insulin-resistance claim. But the Methods (Patients; page not specified) enrolled overweight patients with PCOS, not specifically patients with obesity and infertility, so the claim extends the finding to a population the study did not identify. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The exact cause of PCOS remains unclear, but it is generally reported that IR plays a crucial role in its onset and progression6.”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Introduction
What the sources say
- Supportedcites [6] Li, M. et al. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal. Transduct. Target. Ther. 7 (1), 216 (2022). source
In “IR RELATED DISEASES IN HUMAN,” the review says IR and obesity are believed to play prevalent roles in causing PCOS. It also describes a reinforcing cycle between IR and hyperandrogenemia in PCOS, supporting the claim about its onset and progression. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
101 more claims
Create a free account to see all 160 claims and every source verdict.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 32
- The quote only partly states this claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Changes in hormones
“MD = −0.48”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Changes in hormones
“95% CI −1.98 to −1.50; P < 0.0001”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Safety assessment of GLP-1RAs
“GLP-1RA intervention was not associated with increased diarrhea events when compared to placebo”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Safety assessment of GLP-1RAs
“OR = 13.08; 95% CI 2.06 to 82.80; P = 0.006”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Changes in hormones
“GLP-1 RA intervention was not associated with changes in FAI when compared to those given metformin or placebo”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Changes in hormones
“MD = −1.72; 95% CI −1.94 to −1.50; P = 0.54”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“The meta-analysis included a total of 397 and 330 individuals who received the invention of GLP-1RAs and metformin, respectively, as well as 68 individuals who received a placebo. With respect to GLP-1RAs, 23, 87 and 308 patients respectively received semaglutide, liraglutide and exenatide.”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Study characteristics
Reported 397 · recomputed 418
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Discussion
“While total cholesterol and LDL levels were reduced”
§ Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials > Results > Changes in total cholesterol, HDL, LDL and TG
“GLP-1RA intervention was associated with a reduction in LDL when compared to those given metformin or placebo (MD = 0.01; 95% CI −0.03 to 0.05; P = 0.59; Fig. 6C).”
6 more findings
Create a free account to see every finding of this check.
Citations
Cites
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287 · cited 1×
“Metformin primarily reduces hepatic glucose production, while GLP-1RAs enhance insulin secretion in response to meals 20–22 .”
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 1×
“This highlights the limited role that GLP-1RAs play in lipid management, suggesting that additional lipid-lowering therapies may be necessary for comprehensive metabolic control 27–29 .”
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Self-citationCellular and Molecular Mechanisms of Metformin Action
LaMoia, T. E., & Shulman, G. I. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa023 · Cited by 791
Witchel, S. F., Oberfield, S. E., & Peña, A. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00078 · Cited by 653
Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy
Patel, S. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.04.008 · Cited by 605
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 1×
“The safety outcomes of this meta-analysis highlighted significant gastrointestinal and neurological side effects associated with GLP-1RA interventions 31,32 .”
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
Cited by
Forslund, M., Wändell, P. E., Forsberg, L., Österberg, M., Dagerhamn, J., Wernersson, E., Fredriksson, M. K., Ringborg, A., & Hirschberg, A. L. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag033 · Cited by 38
Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01834-y · Cited by 15
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
Chan, J. L., Masini, I., & Pisarska, M. D. (2026) · Journal of Clinical Investigation · doi:10.1172/jci202824 · Cited by 22
“Indeed, GLP-1 receptor agonists have also been demonstrated to treat metabolic syndrome and decrease BMI, waist circumference, and insulin resistance for individuals with PCOS/PMOS, especially in the setting of obesity (115, 116).”
Abedi, M. M., Patni, M. M., Shajahan, A. N. B., Dube, R., Khadeeja, L., Alabid, I., Kharoufeh, A., Kar, S. S., George, B. T., Bahutair, S. N., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093204 · Cited by 9
“Lin et al. also reported mild gastrointestinal and neurologic adverse effects, including nausea, vomiting, and dizziness, which may further complicate treatment during the periconception period [51].”
Metadata
- Authors
- Lin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B.
- Affiliations
- Youjiang Medical College for Nationalities (CN)
- Chinese University of Hong Kong (HK)
- Imperial College London (GB)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Corresponding author
- Qin, Minzhen
- Tan, Bing
- Venue
- Scientific Reports
- Published
- 2025-05-13
- Volume
- 15
- Issue
- 1
- Pages
- 16512-16512
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC12075827
- OpenAlex
- W4410332077
- Cited by
- 35
- References
- 46
- Citations by year
- 2026: 33 · 2025: 2
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, polycystic ovary syndrome, weight management, insulin resistance, glucose homeostasis, metformin, body mass index, waist circumference, lipid profile, HDL cholesterol, adverse effects, nausea, testosterone
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Insulin, Metformin, Polycystic Ovary Syndrome, Body Mass Index, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1038/s41598-025-99622-4
- The paper
- Lin, S., Deng, Y., Huang, J., Li, M., Sooranna, S. R., Qin, M., & Tan, B. (2025). Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Scientific Reports. https://doi.org/10.1038/s41598-025-99622-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.